-
2022-502779-40-00
5
2023-09-04
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2023-509859-13-00
5
2022-11-09
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-517008-12-00
5
2022-10-14
Newly-diagnosed multiple myeloma (NDMM)
-
2024-514630-21-00
4
2022-08-11
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
-
2023-507698-16-00
5
2021-10-14
Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma (BRUIN CLL-322
-
2023-509120-17-00
5
2021-04-12
Myelofibrosis
-
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2024-516905-22-00
5
2018-10-22
Multiple myeloma
-
2023-506112-40-00
5
2018-09-26
R/R Multiple Myeloma
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer
-
2023-507865-24-00
5
2025-03-28
Advanced (unresectable/metastatic) melanoma
-
2023-506000-50-00
4
2024-09-26
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
-
2023-506185-31-00
10
2024-07-18
Idiopathic pulmonary fibrosis (IPF)
-
2023-509001-76-00
5
2024-07-01
Asthma
-
2023-503614-80-00
5
2023-12-14
Pulmonary Arterial Hypertension
-
2024-510571-37-00
7
2023-12-06
Herpes Simplex
-
2023-503963-41-00
6
2023-10-05
HIV-Infected patients
-
2023-504727-32-00
4
2023-09-18
Acute vulvovaginal candidiasis
-
2022-502024-51-00
5
2023-07-12
Prevention of pregnancy
-
2024-512554-15-00
5
2023-06-21
COVID-19
-
2024-512590-27-00
9
2023-03-08
Non-resectable locally advanced or metastatic HER2-positive breast can
-
2023-504540-33-00
5
2023-03-06
COVID-19
-
2023-508860-31-00
5
2023-02-28
Stage IV colon or rectal adenocarcinoma (mCRC).